AtriCure Inc. (NASDAQ:ATRC) has received a consensus rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $35.75.

A number of research firms recently weighed in on ATRC. BidaskClub lowered AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Zacks Investment Research lowered AtriCure from a “buy” rating to a “sell” rating in a research report on Tuesday, March 5th. Finally, BTIG Research reiterated a “hold” rating on shares of AtriCure in a research report on Tuesday, March 5th.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Investors Inc. PA acquired a new stake in AtriCure during the 3rd quarter worth about $34,000. Ibex Investors LLC acquired a new stake in AtriCure during the 3rd quarter worth about $204,000. Robeco Institutional Asset Management B.V. acquired a new stake in AtriCure during the 4th quarter worth about $190,000. GSA Capital Partners LLP boosted its position in AtriCure by 78.2% during the 3rd quarter. GSA Capital Partners LLP now owns 46,424 shares of the medical device company’s stock worth $1,626,000 after acquiring an additional 20,370 shares during the period. Finally, MetLife Investment Advisors LLC boosted its position in AtriCure by 54.8% during the 3rd quarter. MetLife Investment Advisors LLC now owns 25,182 shares of the medical device company’s stock worth $882,000 after acquiring an additional 8,912 shares during the period. Hedge funds and other institutional investors own 89.47% of the company’s stock.

NASDAQ:ATRC opened at $29.04 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.34 and a quick ratio of 3.78. AtriCure has a 1-year low of $19.22 and a 1-year high of $36.49. The firm has a market capitalization of $1.12 billion, a P/E ratio of -30.89 and a beta of 0.28.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

See Also: Catch-Up Contributions

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.